The effect of trehalose on Fatigue in MS

Investigation of the effect of trehalose on Fatigue in patients with Multiple Sclerosis (MS)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181022041407N8

Enrollment

Registered

2024-08-14

Start date

2024-09-22

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Trehalose 10 g per day for 12 weeks, made by Shaanxi Fruiterco Biotechnology Co.,Ltd. Intervention 2: Control group: Placebo (one sachet of sucrose per day for 12 w

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Suffering from multiple sclerosis (MS) At least 6 months under treatment Age more than 18 Suffering from fatigue EDSS less or equal to 6 Satisfaction for participation in the research project Ability to read

Exclusion criteria

Exclusion criteria: Under treatment for depression

Design outcomes

Primary

Measure	Time frame
Fatigue score. Timepoint: At baseline and after 12 weeks. Method of measurement: Using Modified Fatigue Impact Scale (MFIS).	—

Secondary

Measure	Time frame
Quality of life. Timepoint: At baseline and after 12 weeks. Method of measurement: Using European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L).;Depression and anxiety. Timepoint: At baseline and after 12 weeks. Method of measurement: Using Hospital Anxiety and Depression Scale (HADS).;Ability to walk. Timepoint: At baseline and after 12 weeks. Method of measurement: Multiple Sclerosis Walking Scale-12 (MSWS-12).	—

Measure

Time frame

Quality of life. Timepoint: At baseline and after 12 weeks. Method of measurement: Using European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L).;Depression and anxiety. Timepoint: At baseline and after 12 weeks. Method of measurement: Using Hospital Anxiety and Depression Scale (HADS).;Ability to walk. Timepoint: At baseline and after 12 weeks. Method of measurement: Multiple Sclerosis Walking Scale-12 (MSWS-12).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Emadzadeh

Mashhad University of Medical Sciences

maryamemadzadeh@yahoo.com+98 51 3841 7403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026